Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

As regards tirzepatide, the FDA declared it "does not intend to take action against compounders" mimicking Lilly's Zepbound weight-loss drug "until March 19, 2025," so long as they are acting ...

I'm talking about weight loss drugs. Lilly makes tirzepatide, commercialized under the name Zepbound for weight loss and Mounjaro for type 2 diabetes. But doctors have prescribed either one for ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Other weight loss drugs, such as tirzepatide — sold under the brand ... the US-based healthcare claims database IQVIA PharMetrics Plus for Academics. Data from 2006 to 2020 was reviewed to ...

Eli Lilly’s Mounjaro (tirzepatide) in diabetes, also part of the GLP-1 revolution, with more than $6.3 billion (124%) in year-on-year sales growth, and Vertex’s combination therapy for cystic ...

Saving money on games through PS Plus is easily done if you're a PlayStation Plus member. However, finding the cheapest PlayStation Plus deals on the membership itself is a whole different story.

Gaming online can be a lot of fun, although the one downside if you’re on a console like the PlayStation, is that you’ll have to get a PS Plus subscription to access online services.

LifeMD Inc (LFMD) reported a robust financial performance for the fourth quarter of 2024, significantly surpassing market expectations with an earnings per share (EPS) of $0.21 against a ...

LifeMD Inc (LFMD) reported a robust financial performance for the fourth quarter of 2024, significantly surpassing market expectations with an earnings per share (EPS) of $0.21 against a forecasted ...